INNOVATIVE CELL-BASED URINALYSIS FOR PATIENT ADHERENCE

描述（由申请人提供）：这项小型企业创新研究（sbir - II期）提案的科学和商业目标是开发基于细胞的检测方法，用于检测体液中的生物活性补充和替代药物（CAM）药物。拟议的项目建立在最近一期资金设计和验证的分子分析的基础上。通过体外生物发光成像系统识别体液中CAM药物的策略补充了Swaasth公司开发的另一种药物发现技术，称为基因表达和测量（GEMTM）。总之，这些基于细胞的CAM药物检测技术将使在CAM模式调查中监测遵守研究方案的客观措施的新技术的发展成为可能。swaash Inc.拥有

DESCRIPTION (provided by applicant): The scientific and commercial goal of this small business innovation research (SBIR-Phase II) proposal is to develop cell-based assays for the detection of biologically active complementary and alternative medicine (CAM) agents in body fluids. The proposed project builds on the foundation of a molecular assay designed and validated through a recent Phase I funding. The strategy of identifying CAM agents in body fluids by an in vitro bio-luminescence imaging system complements another drug-discovery technology developed at Swaasth Inc, referred to as Genetic Expression and Measurement (GEMTM). Together, these cell-based CAM agent detection technologies will enable the development of novel technologies in monitoring objective measures of adherence to study-protocol in the investigations of CAM modalities. Swaasth Inc. has successfully developed molecular reagents and high throughput-screening infrastructure required to identify CAM agents. It is anticipated that the availability of GEM system will make effective use of the Phase II funding to further expand the detection of a variety of CAM agents and enhance minimally invasive patient adherence measurements for CAM modalities in clinical settings.